What additional therapy should be recommended for a patient with cystic fibrosis after initial oxygen delivery?

For a patient with cystic fibrosis, the management after initial oxygen delivery often includes addressing the underlying respiratory complications associated with the condition. Tobramycin, which is an antibiotic used to treat bacterial infections, specifically targets Pseudomonas aeruginosa, a common pathogen in cystic fibrosis patients. Albuterol is a bronchodilator that helps relieve bronchospasm and improve airflow, which is critical for patients with obstructed airways due to thick mucus. Dornase alfa is an enzyme that reduces the viscosity of the mucus and helps to clear it from the lungs.

Incorporating these therapies is essential because they directly improve lung function and reduce the risk of respiratory infections, which are prevalent in individuals with cystic fibrosis. The combination of tobramycin, albuterol, and dornase alfa effectively addresses both the infection and mucus clearance, making it a comprehensive treatment approach.

The other therapy options do not focus as effectively on the specific needs of a cystic fibrosis patient in the context of managing respiratory symptoms after oxygen delivery. Emergency intubation should only be considered in life-threatening situations, while intravenous hydration is not specifically indicated for treating the respiratory complications associated with cystic fibrosis. Bronchodilator cocktails might provide symptomatic relief but do not include